Press Release
Press Release
Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015
- Briefing to Discuss Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at the Meeting -
- Cabozantinib and Exelixis-Discovered Cobimetinib to be Subject of Three Presentations -
METEOR Data to be Presented during the ECC 2015 Presidential Session I
As previously announced, detailed data from METEOR will be presented at
the ECC as a late-breaking abstract in the Presidential Session I on
• |
Abstract 4LBA: Late-Breaking Abstract: Cabozantinib versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of the Randomized Phase 3 METEOR Trial |
||||
Toni K. Choueiri, M.D. | |||||
Presidential Session I | |||||
Saturday, September 26, 2015 | |||||
Session from 14:30-16:40 CEST (8:30-10:40 a.m. EDT); presentation expected to begin at 16:20 CEST (10:20 a.m. EDT) |
|||||
Hall D1 |
|||||
Investor/Analyst Webcast to Review METEOR Data
The investor/analyst webcast will be held following the presentation on
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, you may access the webcast at this address: http://edge.media-server.com/m/p/c7qgq2ma/lan/en.
An archived replay of the webcast will be available on the Event
Calendar page under Investors & Media at www.exelixis.com
for one year. A telephone replay of the webcast will be available until
Cobimetinib Data Accepted for Proffered Paper and Poster Sessions
Also at the meeting, Exelixis’ collaborator Genentech, a member of the
The details of the cobimetinib presentations are as follows:
• |
Abstract 25LBA: Late-Breaking Abstract: Impact of Baseline Genetic Heterogeneities on Progression-Free Survival (PFS) in Patients (pts) with Advanced BRAFV600-mutated Melanoma Treated with Cobimetinib (COBI) + Vemurafenib (VEM) in the phase 3 coBRIM Study |
||||
Professor Grant McArthur | |||||
Proffered Paper Session: Melanoma and Skin Cancer I | |||||
Sunday, September 27, 2015 | |||||
Session from 11:30-12:30 CEST (5:30-6:30 a.m. EDT); presentation expected to begin at 12:10 CEST (6:10 a.m. EDT) | |||||
Hall A2 | |||||
|
• |
|
|
Abstract 3340: Treatment beyond Progression in Advanced BRAF-mutated Melanoma with Vemurafenib and Cobimetinib: Results from the BRIM7 Trial |
|
|
|||||
Karl Lewis, M.D. | |||||
Poster Session: Melanoma and Skin Cancer | |||||
Sunday, September 27, 2015 | |||||
Session from 16:45-18:45 CEST (10:45 a.m. - 12:45 p.m. EDT) | |||||
Hall C, Poster 217 | |||||
About Cabozantinib
Cabozantinib inhibits the activity of tyrosine kinases including MET, VEGF receptors, AXL, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
COMETRIQ® (cabozantinib capsules) is currently approved by
the
Important Safety Information, including Boxed WARNINGS
WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE
- Serious and sometimes fatal gastrointestinal perforations and fistulas occur in COMETRIQ-treated patients.
- Severe and sometimes fatal hemorrhage occurs in COMETRIQ-treated patients.
- COMETRIQ treatment results in an increase in thrombotic events, such as heart attacks.
- Wound complications have been reported with COMETRIQ.
- COMETRIQ treatment results in an increase in hypertension.
- Osteonecrosis of the jaw has been observed in COMETRIQ-treated patients.
- Palmar-Plantar Erythrodysesthesia Syndrome (PPES) occurs in patients treated with COMETRIQ.
- The kidneys can be adversely affected by COMETRIQ. Proteinuria and nephrotic syndrome have been reported in patients receiving COMETRIQ.
- Reversible Posterior Leukoencephalopathy Syndrome has been observed with COMETRIQ.
- Avoid administration of COMETRIQ with agents that are strong CYP3A4 inducers or inhibitors.
- COMETRIQ is not recommended for use in patients with moderate or severe hepatic impairment.
- COMETRIQ can cause fetal harm when administered to a pregnant woman.
Adverse Reactions – The most commonly reported adverse drug reactions (≥25%) are diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. The most common laboratory abnormalities (≥25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.
Please see full U.S. prescribing information, including Boxed WARNINGS, at www.COMETRIQ.com/downloads/Cometriq_Full_Prescribing_Information.pdf
Please refer to the full European Summary of Product Characteristics for
full
About
Exelixis and the Exelixis logo are registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150922006486/en/
Source:
Investor Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
Investor Relations and Corporate
Communications
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcommunications.com